The set of data elements (patient initials, suspected medicinal product, other treatments, details of the suspected ADR, details on the reporter, and administrative details) are used for expedited reports to ensure what?

• A. They are optional and may be omitted
• B. They are not necessary for expedited reporting
• C. They form the key data elements to include in expedited reports
• D. They are used only for pharmacovigilance submissions outside trials

Answer: (D)

In expedited reporting, including those specific data elements ensures the report is complete and actionable for regulators. The patient’s initials provide a way to identify the subject while protecting privacy, the suspected medicinal product and any other treatments clarify what exposure may have led to the event, and the details of the adverse reaction describe the safety signal. Details about the reporter and administrative information establish who submitted the report and how to contact the site for follow-up, audit trails, and regulatory correspondence. All of this information together allows rapid, accurate assessment of potential safety issues, proper signal interpretation, and timely regulatory action. They are essential components of expedited reports and are not optional or limited to submissions outside trials.